KMDA +3% in pre-mkt following earlier PR: Kamada Announces a Three-Year $50M Sales Agreement to Supply Plasma to a Leading Biopharmaceutical

KMDA +3% in pre-mkt following earlier PR: Kamada Announces a Three-Year $50M Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies Through Texas Centers, Commercial Sales Starting Q4 2026